Artelo Biosciences Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&D expenses of USD 5.4 million and G&A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of December 31, 2025. On the business side, Artelo reported positive first-in-human Phase 1 single ascending dose data for ART26.12, citing a favorable safety profile and predictable pharmacokinetics, and said it is preparing to open enrollment for a multiple ascending dose study in Q3 2026. The company also announced positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia-cachexia syndrome, and said it received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13 with patent protection through December 2041. For ART12.11, Artelo said it received favorable UK MHRA guidance supporting Phase 1 plans and, pending 2026 toxicology results, plans to initiate human studies with an oral solid dosage form in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.